Issue Shifting the Biopharma Paradigm

Current Issue: Q1 2022

The Next-Generation Therapies Issue

Shifting the Biopharma Paradigm

Welcome to the first digital issue of the new Pharma’s Almanac, bringing our high levels of thought leadership into new spaces. This issue reflects an expansion of our editorial content, including regular columns from the Nice Insight and Pharma’s Almanac teams, in addition to some really illuminating Q&A interviews and articles on a range of innovative, forward-looking topics spanning drug discovery, development, and manufacturing. This issue includes some amazing contributors, so we hope you enjoy!

Also In This Issue

Financial Results

Samsung Biologics Reports First Quarter 2022 Financial Results

Q1’22 revenue of KRW 511.3 billion increased 96% compared to Q1’21. Q1’22 operating profit of KRW 176.4 billion increased 137% compared to Q1’21. Stable business operations and utilization rates across Plants 1, 2, and 3. Proactive investments into long-term growth, capacity, and sustainability. Incheon, S. Korea – Samsung Biologics (KRX: 207940.KS), the world’s leading contract development […]

Automated Visual Inspection

Advancing Visual Inspection of Printed Pharmaceutical Materials

Pharmaceuticals and medical devices require flawless printing of essential information including recipes, batch numbers, and codes, which must also accommodate a range of materials, frequent layout changes, and text in different languages and alphabets, as well as non-textual information, like barcodes and logos. Automated visual inspection systems with state-of-the-art equipment designs and software algorithms enable […]

Column: M&A

Why the Big Shifts in Gene Therapy Investments? It’s Late in the Game

For everyone, entering the market late carries a price. Biopharma market dynamics have shifted focus from fermentation and cell culture to plasmids and viral vectors. There are few assets to buy, and only large-cap private equity (PE) firms and strategic buyers can afford the outlandishly high multiples they come with. Big CDMOs are electing to […]

Column: Clinical Trials

How Artificial Intelligence May Drive the Future of Clinical Trials

Bringing a drug to market is no easy feat, and that’s putting it mildly. Traditional clinical trials are lengthy — taking nearly ten years on average,1 expensive — with an average cost of around $1 billion,1 and inefficient — with around a 10% success rate.1 Despite the level of scientific skill exhibited by some of […]

Column: Regulatory Spotlight

New FDA Guidance on Real World Evidence/Real World Data

As interest in the use of real-world data (RWD) and real-world evidence (RWE) continues to increase, the FDA is publishing draft guidance documents to help sponsors successfully navigate the submission of applications leveraging this “new” type of clinical information. Growing Importance of Real-World Evidence and Real-World Data Serious interest in the use of real-world data […]

Column: New Drug Watch

Alzheimer Drug Still Controversial

Aducanumab (Aduhelm™, Biogen), the first drug shown to reduce amyloid plaques, received accelerated approval from the U.S. FDA in June 2021 for the treatment of Alzheimer’s disease. Despite excitement in the advocacy community, several months later, few prescriptions have been written owing to ongoing questions about the rapid approval and continuing concerns regarding the safety […]

Column: Investment

2021 Was a Great Year for Biotech IPOs, Depending on When You Got Out

Though last year was a rollercoaster for biotech IPOs, 2022 has comparatively leveled off as shares miss 2021’s signature spike. Here’s what investors need to know about this year’s cooler market and the lessons learned from 2021’s top earners. 2021 was a landmark year for biotech IPOs. Companies charted record-breaking launches and gains, with a […]

Column: Regional

Expanding the Cell and Gene Therapy Ecosystem in Philadelphia

The Cell & Gene Therapy and Connected Health Initiative of the Chamber of Commerce for Greater Philadelphia’s CEO Council for Growth is bringing the community together to drive growth in the cell and gene sector with the goal of advancing Greater Philadelphia as a leading global hub in the field. The Original Home of Cell […]

Recombinant Antibody Production

HEK Cells vs. CHO Cells in Recombinant Antibody Production: What’s the Better Choice

The demand for therapeutic proteins is constantly growing and fuels the search for high-quality protein production technologies. However, some researchers are thrown off by the choice between human embryonic kidney (HEK or HEK293) cells and Chinese hamster ovary (CHO) cells for recombinant antibody production. Zurich-based CDMO evitria AG provides a compact overview of which cell line […]

Past Issues

View all Past Issues

The Innovation Issue

View Issue »

Issue #4 | Volume #4 | Q4 2018

The Role of Innovative Technologies

View Issue »

Issue #4 | Volume #3 | Q4 2017

The Outsourcing Issue

View Issue »

Issue #3 | Volume #6 | Q3 2020

The Business Development Issue

View Issue »

Issue #1 | Volume #5 | Q1 2019